Study of Heart and Renal Protection - SHARP

Aims

To determine the effects of cholesterol lowering, with a combination of simvastatin and ezetimibe, on the risk of major vascular complications in patients with chronic kidney diseases.

Methods

SHARP is a randomised placebo-controlled trial among 9,400 individuals recruited from about 300 centres worldwide. The George Institute, in collaboration with the Australia and New Zealand Society of Nephrology, is coordinating and overseeing the recruitment and follow-up of 2081 study participants from Australia, New Zealand, Malaysia and Thailand. Mean follow-up for participants will be four and a half years.

Status/Results

Globally, the SHARP study is fully restricted. 95% of target recruitment achieved in our region. The follow-up of patients is scheduled to continue until 2010 and the results will be reported in 2011.